IDXX Stock Recent News

Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.

Humana delivered better-than-expected second-quarter earnings. Vertex Pharmaceuticals has three potential blockbuster therapies on the way.

Fintel reports that on August 2, 2023, Atlantic Equities downgraded their outlook for Idexx Laboratories (NASDAQ:IDXX) from Overweight to Neutral.

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2023 Earnings Conference Call August 1, 2023 8:30 AM ET Company Participants Jay Mazelsky - President and Chief Executive Officer Brian McKeon - Chief Financial Officer John Ravis - Vice President, Investor Relations Conference Call Participants Nathan Rich - Goldman Sachs Michael Ryskin - Bank of America Ryan Daniels - William Blair John Block - Stifel David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Second Quarter 2023 Earnings Conference Call. As a reminder, today's conference is being recorded.

IDEXX (IDXX) delivers better-than-expected earnings and revenues in the second quarter of 2023, backed by CAG Diagnostics' recurring revenue growth.

The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.67 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $1.56 per share a year ago.

IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

IDEXX Laboratories, a healthcare supplier specializing in veterinary health diagnostics and research, is a potential high-performing compounder due to its wide-moat business model, anti-cyclical customers, strong pricing power, and high free cash flow conversion. Despite not offering dividends, IDEXX has returned nearly 1,000% over the past decade, and its focus on fast-growing veterinary healthcare and aim to increase its installed base of premium instruments could contribute to further revenue expansion.